MedTrace Logo

Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

NCT03706911 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-12-15

No results posted yet for this study

Summary

To evaluate safety and tolerability of VM-1500A-LAI after its single and multiple intramuscular ascending dose to healthy volunteers

Conditions

Interventions

DRUG

VM-1500A-LAI

VM-1500A (parent drug of elsulfavirine) IM injection dosage form

Sponsors & Collaborators

  • Viriom

    lead INDUSTRY

Principal Investigators

  • Elena Smolyarchuk, PhD · I.M. Sechenov First Moscow State Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-21
Primary Completion
2020-03-27
Completion
2020-05-18

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706911 on ClinicalTrials.gov